| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rheumatology 2002; 41: 793-800
© 2002 British Society for Rheumatology
Original Papers |
The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century
ARC Epidemiology Unit, Stopford Building, University of Manchester, Oxford Road, Manchester M13 9PT and
1 Norfolk Arthritis Register, Norfolk and Norwich University Hospital, Norfolk NR4 7UZ, UK
Background. It is 40 yr since the last age- and sex-specific estimates of the prevalence of rheumatoid arthritis (RA) for the UK were published. Since then the classification criteria for RA have been revised and there has been evidence of a fall in the incidence of RA, especially in women.
Objectives. To estimate the age- and sex-specific point prevalence of RA (defined as fulfilment of a modification of the 1987 ACR classification criteria for RA on the day of assessment). The estimate was made in the primary care setting in Norfolk, UK.
Methods. A stratified random sample was drawn from seven age and gender bands. The 7050 individuals selected were mailed a screening questionnaire. Positive responders were invited to attend for a clinical examination. The sample was matched against the names in the Norfolk Arthritis Register (NOAR), a register of incident cases of inflammatory polyarthritis which has been in existence since 1990.
Results. The overall response rate was 82%. Sixty-six cases of RA were identified. Extrapolated to the population of the UK, the overall minimum prevalence of RA is 1.16% in women and 0.44% in men. A number of incident cases of RA previously notified to NOAR were not identified as cases in the survey because they had entered into treatment-induced remission. In addition, some cases who failed to attend for examination had significant disability. These prevalence figures are therefore an underestimate.
Conclusions. The prevalence of RA in women, but not in men, in the UK may have fallen since the 1950s.
Correspondence to: D. Symmons.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. Westhoff, M. Schneider, H. Raspe, H. Zeidler, C. Runge, T. Volmer, and A. Zink Advance and unmet need of health care for patients with rheumatoid arthritis in the German population--results from the German Rheumatoid Arthritis Population Survey (GRAPS) Rheumatology, June 1, 2009; 48(6): 650 - 657. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. McLean-Tooke, C. Aldridge, S. Waugh, G. P. Spickett, and L. Kay Methotrexate, rheumatoid arthritis and infection risk--what is the evidence? Rheumatology, May 15, 2009; (2009) kep101v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Deighton, R. O'Mahony, J. Tosh, C. Turner, M. Rudolf, and on behalf of the Guideline Development Group Management of rheumatoid arthritis: summary of NICE guidance BMJ, March 16, 2009; 338(mar16_1): b702 - b702. [Full Text]
|
|
|
|
|
|
H. John, E. D. Hale, G. J. Treharne, and G. D. Kitas Patient education on cardiovascular aspects of rheumatoid disease: an unmet need Rheumatology, October 1, 2007; 46(10): 1513 - 1516. [Full Text] [PDF]
|
|
|
|
 |
|
 S A Chambers, S C Charman, A Rahman, and D A Isenberg Development of additional autoimmune diseases in a multiethnic cohort of patients with systemic lupus erythematosus with reference to damage and mortality Ann Rheum Dis, September 1, 2007; 66(9): 1173 - 1177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Brennan, N. Bansback, R. Nixon, J. Madan, M. Harrison, K. Watson, and D. Symmons Modelling the cost effectiveness of TNF-{alpha} antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry Rheumatology, August 1, 2007; 46(8): 1345 - 1354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Pacher, J. S. Beckman, and L. Liaudet Nitric Oxide and Peroxynitrite in Health and Disease Physiol Rev, January 1, 2007; 87(1): 315 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Andrianakos, P. Trontzas, F. Christoyannis, E. Kaskani, Z. Nikolia, E. Tavaniotou, A. Georgountzos, P. Krachtis, and for the ESORDIG study group Prevalence and management of rheumatoid arthritis in the general population of Greece--the ESORDIG study Rheumatology, December 1, 2006; 45(12): 1549 - 1554. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K M J Douglas, E Ladoyanni, G J Treharne, E D Hale, N Erb, and G D Kitas Cutaneous abnormalities in rheumatoid arthritis compared with non-inflammatory rheumatic conditions Ann Rheum Dis, October 1, 2006; 65(10): 1341 - 1345. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. G. Witney, G. J. Treharne, M. Tavakoli, A. C. Lyons, K. Vincent, D. L. Scott, and G. D. Kitas The relationship of medical, demographic and psychosocial factors to direct and indirect health utility instruments in rheumatoid arthritis Rheumatology, August 1, 2006; 45(8): 975 - 981. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. V. O'Brien, P. Jones, R. Mullis, D. Mulherin, and K. Dziedzic Conservative hand therapy treatments in rheumatoid arthritis--a randomized controlled trial Rheumatology, May 1, 2006; 45(5): 577 - 583. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Edwards, N. K. Arden, D. Fisher, J. C. Saperia, I. Reading, T. P. Van Staa, and C. Cooper The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database Rheumatology, November 1, 2005; 44(11): 1394 - 1398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Treharne, G. D. Kitas, A. C. Lyons, and D. A. Booth Well-being in Rheumatoid Arthritis: The Effects of Disease Duration and Psychosocial Factors J Health Psychol, May 1, 2005; 10(3): 457 - 474. [Abstract] [PDF]
|
|
|
|
|
|
A. Brennan, N. Bansback, A. Reynolds, and P. Conway Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK Rheumatology, January 1, 2004; 43(1): 62 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Zauli, S. Zucchini, E. Manfredini, A. Grassi, G. Ballardini, M. Fusconi, and F. B. Bianchi Prevalence of rheumatoid arthritis Rheumatology, May 1, 2003; 42(5): 696 - 697. [Full Text] [PDF]
|
|
|
|
|
|
D. Symmons Reply Rheumatology, May 1, 2003; 42(5): 697 - 697. [Full Text] [PDF]
|
|